Louisiana 2023 Regular Session

Louisiana Senate Bill SR96

Introduced
5/16/23  
Refer
5/17/23  
Refer
5/17/23  
Report Pass
5/24/23  
Report Pass
5/24/23  
Passed
5/25/23  

Caption

Requests the Louisiana Department of Health to study acute and long-term adverse health events related to medical marijuana.

Impact

If enacted, SR96 could lead to significant changes in how medical marijuana and kratom are regulated in Louisiana. As the state has seen flourishing acceptance and usage of these substances over the years, the resolution highlights the importance of grounding regulatory practices in solid empirical research related to health outcomes. The findings from the proposed study would likely shape future legislative actions and health policies, fostering a more informed approach toward these substances while ensuring public safety.

Summary

Senate Resolution 96 (SR96) urges the Louisiana Department of Health to conduct a comprehensive study examining the acute and long-term adverse health effects associated with medical marijuana, THC-containing hemp, and kratom. The necessity for this research arises from the expanded use of medical marijuana and other similar substances, prompting concerns about their health ramifications. Given the recent legislative changes which have broadened the scope of medical marijuana usage, tracking its impact on public health has become imperative.

Sentiment

The sentiment surrounding SR96 has been generally positive, with support for heightened scrutiny of substances like medical marijuana and kratom from various health advocates. This resolution is seen as a proactive measure to protect public health and ensure that any adverse effects are well documented before moving forward with further legislative action. However, there may be underlying tension among proponents of medical marijuana who fear that excessive regulation could hinder access for patients in need.

Contention

Notable contention centers on the regulatory balance required to manage medical marijuana and kratom effectively. Some stakeholders may argue that an extensive regulatory response, predicated on the study's findings, might lead to limitations that could negatively affect patient access and treatment options. Additionally, debates may arise about the validity and interpretation of health risks associated with these substances, given their differing perceptions in societal and medical contexts.

Companion Bills

No companion bills found.

Previously Filed As

LA HCR67

Requests the Louisiana Department of Health to study and report on gaps in acute healthcare access for individuals with intellectual and developmental disabilities

LA SB270

Provides for access to medical marijuana for terminally ill patients in a healthcare facility. (8/1/26)

LA SR32

Requests the Louisiana Department of Health and Department of Veterans Affairs to implement policies for the health and safety of long-term care facility residents.

LA SCR27

Requests the Louisiana Department of Health to increase the Medicaid reimbursement rate for breast pumps and related supplies.

LA HR290

HEALTH: Requests the Louisiana Department of Health to study the effects of gender affirming therapy on mental health

LA SR194

Requests the Louisiana Department of Health to review and provide certain information to the Senate regarding Medicaid managed care contracts.

LA SR63

Requests the Louisiana Department of Health to study the feasibility of providing buprenorphine to paramedics.

LA HR267

HEALTH: Requests the Louisiana Department of Health to study prevention and reduction of diabetes-related amputations

LA SR209

Requests the Louisiana Department of Health to study the impacts of a prohibition on PBM ownership of pharmacies.

LA HCR71

Requests the Louisiana Dept. of Health to review the implementation of existing law and guidance regarding pregnancy-related emergency medications in hospital and acute care settings

Similar Bills

LA HB657

Provides relative to fees collected by the Louisiana Department of Health related to the sale of therapeutic marijuana (EN +$225,000 SG RV See Note)

LA HB661

Provides relative to fees collected by the Louisiana Department of Health

LA HCR111

DRUGS: Creates the Louisiana Recreational Cannabis Policy Task Force

LA HB627

Provides for the Louisiana Cannabis Pilot Program (OR INCREASE SG RV See Note)

LA HB623

Provides for a three-tier system of permitting for the producers, manufacturers, and wholesalers of vapor products (EN NO IMPACT GF EX See Note)

LA HB373

Provides for the Louisiana Cannabis Pilot Program (OR INCREASE SG RV See Note)

LA SB270

Provides for access to medical marijuana for terminally ill patients in a healthcare facility. (8/1/26)

LA HB384

Provides relative to disciplinary penalties for certain public school students found to be in possession of certain substances on school property